Innovations Drugs

ICMR Licenses Three Indigenous Biomedical Technologies to Emcure and Biological E

ICMR has licensed SHetA2, a novel anti-HPV therapy for Cervical Intraepithelial Neoplasia (CIN), to Emcure Pharmaceuticals and two next-generation vaccine technologies against enteric bacterial infections, developed at ICMR-NIRBI, Kolkata, to Biological E.